Showing results (51-60 of 75) with videos related to
Sort By:
Pageof 8
Journal for Immunotherapy of Cancer|September 23, 2024
MTA-cooperative PRMT5 inhibitors enhance T cell-mediated antitumor activity in MTAP-loss tumorsSi Chen, Jiakai Hou, Roshni Jaffery, et al.Science Advances|March 2, 2022
Clinically translatable cytokine delivery platform for eradication of intraperitoneal tumorsAmanda M Nash, Maria I Jarvis, Samira Aghlara-Fotovat, et al.Clinical Immunology (Orlando, Fla.)|December 19, 2023
Faslpr gene dosage tunes the extent of lymphoproliferation and T cell differentiation in lupusRitu Bohat, Xiaofang Liang, Yanping Chen, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2012
BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in miceChengwen Liu, Weiyi Peng, Chunyu Xu, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2013
BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanomaDennie T Frederick, Adriano Piris, Alexandria P Cogdill, et al.Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 8, 2018
Multiregion gene expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancerWon-Chul Lee, Lixia Diao, Jing Wang, et al.Cell Reports. Medicine|December 20, 2023
PRMT blockade induces defective DNA replication stress response and synergizes with PARP inhibitionYang Li, Lacey E Dobrolecki, Christina Sallas, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2019
A Novel Mitochondrial Inhibitor Blocks MAPK Pathway and Overcomes MAPK Inhibitor Resistance in MelanomaY N Vashisht Gopal, Seth Gammon, Rishika Prasad, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 1, 2017
The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung CancerTina Cascone, Li Xu, Heather Y Lin, et al.Journal of the National Cancer Institute|December 22, 2017
The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer ImmunotherapyJodi A McKenzie, Rina M Mbofung, Shruti Malu, et al.Pageof 8